Pharmaceuticals Global News & Press Release Distribution

Pharmaceuticals

All
APAC

SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Cancer

SEOUL, South Korea, May 9, 2024 /PRNewswire/ -- SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a new drug for polymer nanoparticle anticancer under clinical trial. SNB-101 ...

2024-05-10 12:00 1460

SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Cancer

Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition cost

* Adalimumab-aaty will be priced at an 85% discount to HUMIRA® (adalimumab) * Branded and unbranded versions of Celltrion USA's adalimumab biosimilar help provide more affordable options for patients JERSEY CITY, N.J., May 9, 2024 /PRNewswire/ -- CelltrionUSA announced today that adalimumab-aa...

2024-05-10 07:41 1369

FDA Clears the Individualized Nomogram for Rika Plasma Donation System

The latest innovation is anticipated to increase collection volume without increasing collection time * Rika's individualized nomogram, iNomi, can enable plasma donors to donate the right amount of plasma on any given day based on height, weight and hematocrit. * The Rika Plasma Donation Sys...

2024-05-09 20:00 1372

FDA Clears the Individualized Nomogram for Rika Plasma Donation System

Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines

Publication in Human Vaccines and Immunotherapeutics highlights progress in understanding tumour biology and vaccine technologies since the pandemic OXFORD, England, May 9, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in pr...

2024-05-09 15:30 2028

Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

TAIPEI, May 9, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into an exclusive licensing agreement with Tabuk Pharmaceuticals Manufacturing Company ("Tabuk"), for exclusive rights to the commercialization of clobetasol...

2024-05-09 15:00 2092

NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia

SHANGHAI and LEXINGTON, Mass. , May 8, 2024 /PRNewswire/ -- NeuShen Therapeutics (the "Company"), a clinical-stage global biotechnology company dedicated to pioneering treatments for neurological and psychiatric disorders, today announced the dosing of the first healthy volunteer inAustralia in t...

2024-05-08 21:00 1468

TiumBio Announces Positive Topline Data from Phase 2a Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain

* The study (NCT05138562) met its primary endpoint of change of dysmenorrhea (menstrual pain) score from baseline to 12 weeks compared to placebo across all tested doses (120 mg, 240 mg, and 320 mg) * Merigolix is expected to emerge as a best-in-class treatment based on its excellent pain re...

2024-05-08 20:00 1237

Minghui Pharmaceutical to Present the Phase I/II Study of MHB088C (B7-H3 ADC) for the Treatment of Patients with Recurrent or Metastatic Solid Tumors in Late-breaking Oral Presentation at the 2024 ASCO Annual Meeting

SHANGHAI, May 8, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company focused on autoimmune diseases and oncology, will feature Dr.Lin Shen from Beijing Cancer Hospital at the upcoming ASCO Annual Meeting inChicago. Dr. Shen will present the results f...

2024-05-08 18:18 6481

FDA Grants Orphan Drug Designation to 9MW2821

SHANGHAI, May 7, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel Nectin-4-targeting ADC (R&D code: 9MW2821) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Adminis...

2024-05-07 22:00 1191

Meihua International Medical Technologies Co., Ltd. to Present at the Emerging Growth Conference on May 9, 2024

Meihua International Medical Technologies Co., Ltd. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. YANGZHOU, China, May 7, 2024 /PRNewswire/ -- Meihua International Medical Tech...

2024-05-07 21:08 1563

GC Genome to Present New Clinical Data on Colorectal Cancer Detection at the ASCO Annual Meeting 2024

YONGIN, South Korea, May 7, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that it will present the new clinical data of its AI-based liquid biopsy platform on colorectal cancer detection at the 2024 American Society of Clinical Oncology (ASCO) Annual ...

2024-05-07 13:27 1359

HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease

* HanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Phase III VELOS-3 study. * Tanfanercept demonstrated statistically significant improvement on the secondary outcome measure, Schirmer testing...

2024-05-03 19:00 2335

Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint

BEIJING and SHANGHAI and BOSTON, April 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online. Prof. Yuankai Shi, chief ...

2024-05-01 08:59 1459

Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) - and Upcoming Scientific Presentations

SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Eluminex Biosciences (Eluminex), a privately-held biotechnology company focused on the development of advanced protein therapeutics for vision-threatening diseases and dermal facial aesthetics announced the acceptance of their EB-105...

2024-04-30 23:00 2560

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

SHENZHEN, China, April 30, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative product Chidamide (Epidaza®) , an oral subtype-selective histone deacetylase (HDAC) inhibitor, combined with R-C...

2024-04-30 20:55 1586

A Potential First-In-Class Drug: CDE Approved Single-Arm Pivotal Clinical Study of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs

NANJING, China, April 30, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights has received approval to co...

2024-04-30 20:16 1591

A Potential First-In-Class Drug: CDE Approved Single-Arm Pivotal Clinical Study of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs

HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update

* Delivered solid performance to start 2024, with record-breaking first quarter revenue of34.1 billion KRW. Strong sales momentum continued from key products, funding investments in ongoing R&D programs. * Phase 3 VELOS-4 study of tanfanercept in dry eye disease expected to be initiated in th...

2024-04-30 19:00 1438

I-MAB Filed 2023 Annual Report on Form 20-F

ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has filed...

2024-04-30 19:00 2906

111 to Announce First Quarter 2024 Unaudited Financial Results on May 23, 2024 - Conference Call to Follow

SHANGHAI, April 30, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial result...

2024-04-30 14:30 1488

WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment

* The Company demonstrated a deep commitment to achieving ESG success in partnership with global clients, creating long-term value for all stakeholders. * The Company made remarkable progress in tackling climate change, achieving a 29% intensity reduction of Scope 1 and Scope 2 greenhouse gas ...

2024-04-30 10:55 1537

1 ... 16 17 181920 21 22 ... 126

Week's Top Stories

Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies

[Picked up by 284 media titles]

2024-11-20 09:00